S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market

Lucid Diagnostics (LUCD) Competitors

$0.80
0.00 (0.00%)
(As of 04/19/2024 ET)

LUCD vs. ICU, CODX, CTCX, CTSO, DRIO, MDAI, LNSR, MODD, DXR, and RVP

Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include SeaStar Medical (ICU), Co-Diagnostics (CODX), Carmell (CTCX), Cytosorbents (CTSO), DarioHealth (DRIO), Spectral AI (MDAI), LENSAR (LNSR), Modular Medical (MODD), Daxor (DXR), and Retractable Technologies (RVP). These companies are all part of the "surgical & medical instruments" industry.

Lucid Diagnostics vs.

Lucid Diagnostics (NASDAQ:LUCD) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings.

Lucid Diagnostics presently has a consensus price target of $2.75, indicating a potential upside of 245.26%. Given Lucid Diagnostics' higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than SeaStar Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
SeaStar Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

In the previous week, SeaStar Medical had 4 more articles in the media than Lucid Diagnostics. MarketBeat recorded 6 mentions for SeaStar Medical and 2 mentions for Lucid Diagnostics. SeaStar Medical's average media sentiment score of 0.59 beat Lucid Diagnostics' score of 0.08 indicating that SeaStar Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lucid Diagnostics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
SeaStar Medical
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

SeaStar Medical has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -2,169.07%. SeaStar Medical's return on equity of 0.00% beat Lucid Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lucid Diagnostics-2,169.07% -901.79% -121.11%
SeaStar Medical N/A N/A -961.93%

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are owned by institutional investors. 4.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 4.5% of SeaStar Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

SeaStar Medical has lower revenue, but higher earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lucid Diagnostics$2.43M15.81-$52.67M-$1.27-0.63
SeaStar MedicalN/AN/A-$23.01M-$1.21-0.33

Lucid Diagnostics received 24 more outperform votes than SeaStar Medical when rated by MarketBeat users. However, 100.00% of users gave SeaStar Medical an outperform vote while only 59.52% of users gave Lucid Diagnostics an outperform vote.

CompanyUnderperformOutperform
Lucid DiagnosticsOutperform Votes
25
59.52%
Underperform Votes
17
40.48%
SeaStar MedicalOutperform Votes
1
100.00%
Underperform Votes
No Votes

Lucid Diagnostics has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.18, meaning that its stock price is 218% less volatile than the S&P 500.

Summary

Lucid Diagnostics and SeaStar Medical tied by winning 8 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LUCD vs. The Competition

MetricLucid DiagnosticsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$38.43M$3.69B$4.89B$7.32B
Dividend YieldN/A2.18%2.93%3.96%
P/E Ratio-0.639.53146.0314.69
Price / Sales15.8155.772,467.5282.00
Price / CashN/A43.1647.3134.38
Price / Book-1.694.224.564.15
Net Income-$52.67M$4.44M$104.37M$214.00M
7 Day Performance-1.55%-3.81%-4.52%-3.51%
1 Month Performance-28.24%-8.24%-6.80%-6.05%
1 Year Performance-47.94%12.82%6.60%3.98%

Lucid Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ICU
SeaStar Medical
0 of 5 stars
$0.71
+7.6%
$5.00
+603.9%
-79.2%$39.15MN/A0.009News Coverage
Gap Down
CODX
Co-Diagnostics
2.7486 of 5 stars
$1.17
-0.8%
$2.50
+113.7%
-23.8%$36.57M$6.81M-0.97155
CTCX
Carmell
0 of 5 stars
$2.20
-8.7%
N/AN/A$42.35MN/A0.0014Gap Down
High Trading Volume
CTSO
Cytosorbents
1.3105 of 5 stars
$0.80
-8.1%
$2.50
+213.4%
-73.9%$43.31M$36.35M-1.25186Positive News
Gap Up
DRIO
DarioHealth
1.2399 of 5 stars
$1.18
+3.5%
$5.37
+354.8%
-68.2%$34.74M$20.35M-1.15276
MDAI
Spectral AI
3.6166 of 5 stars
$1.98
-0.5%
$4.00
+102.0%
N/A$34.59M$18.06M0.0078Positive News
LNSR
LENSAR
1.9123 of 5 stars
$3.02
-4.1%
$8.00
+164.9%
+27.7%$34.43M$42.16M-1.69130
MODD
Modular Medical
3.0512 of 5 stars
$1.55
-1.3%
$4.25
+174.2%
-9.4%$33.94MN/A-1.6037News Coverage
DXR
Daxor
0 of 5 stars
$9.55
+0.5%
N/AN/A$45.27MN/A0.00N/A
RVP
Retractable Technologies
0 of 5 stars
$1.07
+0.9%
N/A-42.4%$32.03M$43.60M-4.46190Analyst Report
News Coverage

Related Companies and Tools

This page (NASDAQ:LUCD) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners